> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Biosphere Portable Bioreactor: The Pentagon Biomanufacturing Pivot - URL: https://nexi.fund/biosphere-portable-bioreactor-2026/ - Published: 2026-07-22T05:50:40.000Z - Updated: 2026-07-22T05:50:40.000Z - Description: The US military wants to grow its own supplies using microbes instead of supply chains. Biosphere portable bioreactor contract shows how. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-statistic, #track-F The Pentagon has poured $965.2 million into biomanufacturing since 2021\. Three initiatives. Two of them end in 2027 and 2028\. And a startup called Biosphere is building the most concrete piece of it, and it fits in a shipping container. ๐ŸŽฏ The US military wants to grow its own supplies (food, fuel, even medicines) at the point of need, using microbes instead of supply chains. California-based Biosphere has won a $9 million DoD contract to build portable UV-sterilized bioreactors that convert air, water, and electricity into protein rations for forward-deployed troops. This is not a side project. The Pentagon has designated biomanufacturing one of six critical technology focus areas and is building a domestic bioindustrial base through programs like DARPA Switch, BioMADE, and T-BRSC. Biomanufacturing is not a new capability. The US Army used bacteria to produce acetone for explosives in 1916\. What is new is the convergence of three trends: synthetic biology tools that give engineers precise genetic control, AI that accelerates strain design, and a strategic imperative to reduce dependence on foreign petrochemical supply chains. The numbers are stark. The DoD currently relies on petrochemicals for virtually every category of consumable โ€” pharmaceuticals, food packaging, textiles, fuels, and structural materials. A 2026 GAO report found that the US lacks sufficient pilot-scale biomanufacturing infrastructure to advance promising biotechnology projects from the laboratory to commercial production. Of the $965.2 million the DoD has invested since 2021, most has gone to early-stage research and planning. None of the three major initiatives โ€” BioMADE, the Tri-Service Biotechnology for a Resilient Supply Chain (T-BRSC), and the Distributed Bioindustrial Manufacturing Program (DBIMP) โ€” has reached operational production yet. That is where Biosphere enters. ## The reactor problem Every bioreactor in commercial use today traces its design lineage to the steam-sterilized vats built for penicillin production in the 1940s. Steam-in-place sterilization requires boilers, hundreds of valves, miles of piping, and massive capital expenditure. A single production-scale stainless steel bioreactor can cost tens of millions of dollars. This cost structure has constrained biomanufacturing to centralized facilities serving large markets, making it uneconomical to deploy bioreactors where they are actually needed โ€” at the point of consumption. Biosphere, founded in 2022 by materials scientist Brian Heligman and molecular biologist Arye Lipman, solved the sterilization problem from first principles. Instead of steam, the company uses ultraviolet light to create aseptic conditions inside the reactor. UV sterilization eliminates the need for pressure vessels, boilers, and complex piping. The result is a reactor that costs 10 times less than conventional equipment, uses 33 percent fewer valves and pipes, and sterilizes six times faster. The company validated the technology at benchtop scale, advanced to pilot-scale clean-in-place systems, and is now building a 20,000-liter demonstration facility. ## $9 million and a 42-month clock In May 2026, the US Army Combat Capabilities Development Command (DEVCOM) Soldier Center awarded Biosphere a $9 million contract under the Manufacturing Science and Technology Program. The 42-month contract funds the design, development, and demonstration of field-deployable bioreactors that can produce protein-based food rations using air, water, and electrical energy as inputs. The target: 2,800 calories per day per person for up to 18 troops, with a planned scale-up to 250 personnel. The prototype must include continuous UV sterilization, water and media recycling, and downstream processing to convert biomass into shelf-stable rations. As we wrote in July, the broader theme of autonomous biomanufacturing for defence applications is gaining momentum. The same week Biosphere announced its NovoNutrients acquisition, DARPA published its Switch program solicitation for run-time reprogrammable biomanufacturing platforms. This is already Biosphere's second DoD contract. The company received a $1.5 million DoD award in 2024, shortly after emerging from stealth with $8.8 million in seed funding led by Lowercarbon Capital and Founders Fund. $9M DoD contract value โ†‘ 6ร— vs 2024 contract #### Biosphere portable bioreactor funding From $1.5M (2024) to $9M (2026), the escalation mirrors the Pentagon's growing urgency around contested logistics. ยท *GAO, AgFunderNews, 2026* ## Gas fermentation and the NovoNutrients acquisition Thirty days after the DoD grant was announced, it acquired the assets of NovoNutrients, a defunct gas fermentation startup. The deal brought in a loop reactor pilot plant at FEL3 design readiness, years of operational data on hydrogen-oxidizing bacteria, and deep expertise in gas-liquid mass transfer โ€” a critical capability for converting gaseous feedstocks into biomass at scale. NovoNutrients' technology was designed for exactly the use case Biosphere is pursuing: efficient transfer of gaseous feedstocks into biological systems without the energy penalty of traditional mechanically agitated reactors. The acquisition gives it a foundation it would have taken years and millions in R&D to build internally. > The cost and complexity of legacy biomanufacturing systems is the major constraint to practical deployment. By simplifying production with our UV reactor architecture, we can reduce the scale required for economical facilities, unlocking streamlined deployment for distributed bioprocessing.โ€” Brian Heligman, PhD, co-founder and CEO, Biosphere ## DARPA and the programmable biomanufacturing ecosystem Biosphere is not operating in isolation. DARPA's Switch program, launched in July 2024, is building run-time reprogrammable biomanufacturing platforms that can toggle between feedstocks and products without hardware changes. The 36-month program aims to enable opportunistic consumption (switching between available feedstocks), need-driven manufacturing (toggling between products), and continuous production with long-term stability. The Switch program complements older DARPA efforts like Living Foundries (2010โ€“2021), which produced over 1,630 molecules for military applications and transitioned technologies to five military research teams. Together, these programs represent a deliberate push to decouple the DoD from petrochemical supply chains that depend on an increasingly concentrated set of foreign suppliers. The Army's DEVCOM Chemical Biological Center is simultaneously building biomanufacturing pilot plant capacity in partnership with MIT, and the Army SBIR program has an active solicitation for automated forward-deployed biomanufacturing units capable of producing nutrition at the point of need. ๐Ÿ“Š **Key signals to track** Biosphere's 20,000-liter demo facility comes online โ€” proof that UV-sterilized reactors can operate at commercial scale DARPA Switch program transitions from Phase 1 (tool development) to Phase 2 (integrated platform demonstration) โ€” expected late 2026 DoD biotechnology roadmap due by September 2026 โ€” will clarify funding priorities beyond BioMADE/T-BRSC/DBIMP sunset dates Biosphere delivers first food samples to Army Combat Feeding Division for evaluation โ€” 18-month milestone in the 42-month contract ### What happens when the bioreactor fits in a Humvee The implications extend beyond food. Its platform (modular, low-cost, UV-sterilized) can be adapted to produce fuels, industrial chemicals, pharmaceuticals, and structural materials. The same 20,000-liter reactor design that makes protein rations could make battlefield medicines, bioplastics for forward operating bases, or even construction materials using bioengineered cement. The DoD's planned $300 million-plus biomanufacturing budget for fiscal year 2026, combined with the forthcoming biotechnology roadmap, suggests this is the beginning of a sustained capability build, not a one-off procurement. Biosphere, with its dual commercial-defence posture and growing IP portfolio, is positioned as an infrastructure supplier for whatever comes next, not just a single-contract vendor. ### Development scenarios #### ๐ŸŸข Optimistic scenario (30%) Biosphere delivers prototype within 30 months. UV-sterilized reactor architecture becomes DoD standard for forward-deployed biomanufacturing. Multiple contracts follow for fuel and pharmaceutical production. DARPA Switch platform integrates with Biosphere hardware for fully reprogrammable biomanufacturing. **Implications:** $100M+ in cumulative DoD biomanufacturing contracts by 2028, with Biosphere as a prime platform supplier. #### ๐ŸŸก Base-case scenario (50%) Biosphere meets contract milestones at 36โ€“42 months. Prototype validated but not yet deployed operationally. NovoNutrients gas fermentation IP proves valuable for future bids. DoD continues biomanufacturing investment through DBIMP and successor programs, but Congress defers full-scale procurement until after the biotechnology roadmap is published. **Implications:** Biosphere secures follow-on contracts at $5Mโ€“15M per phase. Commercial bioreactor sales to industrial fermentation customers become primary revenue driver before defence procurement ramps. #### ๐Ÿ”ด Pessimistic scenario (20%) UV sterilization fails to maintain aseptic conditions in field environments with dust, temperature extremes, and limited clean water. Gas fermentation yields fall short of nutritional requirements. DoD priorities shift following the September 2026 biotechnology roadmap, reallocating biomanufacturing investment to different technology approaches. **Implications:** Biosphere pivots back to commercial industrial fermentation market. DoD contract continues but at reduced scope. NovoNutrients acquisition creates modest write-down. ### Sources [ DARPA Switch: Reprogrammable Biomanufacturing for Defense Needs DARPA's Switch program develops run-time reprogrammable biomanufacturing platforms to enable flexible production switching between feedstocks and products for national security applications. DARPA ](https://www.darpa.mil/research/programs/switch?ref=nexi.fund) Primary source for DARPA's biomanufacturing strategy and the Switch program objectives that frame the DoD's broader bioindustrial buildout. [ Biosphere Expands Biomanufacturing Platform with NovoNutrients Acquisition Official press release detailing Biosphere's acquisition of NovoNutrients' gas fermentation assets, loop reactor pilot plant, and strategic rationale for the deal. GlobeNewswire / Biosphere ](https://www.globenewswire.com/news-release/2026/06/30/3319744/0/en/Biosphere-Expands-Biomanufacturing-Platform-with-NovoNutrients-Acquisition.html?ref=nexi.fund) Official company source for the NovoNutrients acquisition timeline, deal structure, and CEO commentary. [ Biosphere โ€” UV-Sterilization Technology Technical overview of Biosphere's UV sterilization platform: 10x cost reduction, 33% fewer valves, 6x faster sterilization cycles. Biosphere ](https://www.biosphere.io/technology?ref=nexi.fund) Primary technical source for Biosphere's reactor specifications, performance metrics, and design philosophy.